Literature DB >> 20616342

Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Anna Johansson1, Stina Rudolfsson, Peter Hammarsten, Sofia Halin, Kristian Pietras, Jonathan Jones, Pär Stattin, Lars Egevad, Torvald Granfors, Pernilla Wikström, Anders Bergh.   

Abstract

Mast cells affect growth in various human tumors, but their role in prostate cancer (PC) is unclear. Here, we identify mast cells as independent prognostic markers in PC using a large cohort of untreated PC patients with a long follow-up. By analyzing mast cells in different tissue compartments, our data indicate that intratumoral and peritumoral mast cells have anti- opposed to protumor properties. Intratumoral mast cells negatively regulate angiogenesis and tumor growth, whereas peritumoral mast cells stimulate the expansion of human prostate tumors. We also observed mast cell recruitment particularly to the peritumoral compartment in men during the formation of castrate-resistant prostate tumors. In our ortothopic rat model, mast cells accumulated in the peritumoral tissue where they enhanced angiogenesis and tumor growth. In line with this, prostate mast cells expressed high levels of the angiogenic factor FGF-2. Similar to the situation in men, mast cells infiltrated rat prostate tumors that relapsed after initially effective castration treatment, concurrent with a second wave of angiogenesis and an up-regulation of FGF-2. We conclude that mast cells are novel independent prognostic markers in PC and affect tumor progression in animals and patients. In addition, peritumoral mast cells provide FGF-2 to the tumor micro environment, which may contribute to their stimulating effect on angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616342      PMCID: PMC2913352          DOI: 10.2353/ajpath.2010.100070

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma.

Authors:  Anak Iamaroon; Surawut Pongsiriwet; Sumana Jittidecharaks; Komkham Pattanaporn; Sangsom Prapayasatok; Sitthichai Wanachantararak
Journal:  J Oral Pathol Med       Date:  2003-04       Impact factor: 4.253

Review 2.  Immunomodulatory mast cells: negative, as well as positive, regulators of immunity.

Authors:  Stephen J Galli; Michele Grimbaldeston; Mindy Tsai
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

Review 3.  Pharmacologic modulation of inflammatory mediator release by rat mast cells.

Authors:  T J Sullivan; C W Parker
Journal:  Am J Pathol       Date:  1976-11       Impact factor: 4.307

4.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

5.  Activation of mast cell K+ channels through multiple G protein-linked receptors.

Authors:  Y X Qian; M A McCloskey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

6.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy.

Authors:  Pernilla Wikström; Nina Ohlson; Pär Stattin; Anders Bergh
Journal:  Prostate       Date:  2007-09-01       Impact factor: 4.104

8.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

Review 9.  Mesenchymal-epithelial interactions: past, present, and future.

Authors:  Gerald R Cunha
Journal:  Differentiation       Date:  2008-06-28       Impact factor: 3.880

10.  Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

Authors:  D Ribatti; A Vacca; B Nico; F Quondamatteo; R Ria; M Minischetti; A Marzullo; R Herken; L Roncali; F Dammacco
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  79 in total

Review 1.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 2.  Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer.

Authors:  Carole A Oskeritzian
Journal:  Mol Immunol       Date:  2014-04-22       Impact factor: 4.407

3.  Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.

Authors:  Qiang Dang; Lei Li; Hongjun Xie; Dalin He; Jiaqi Chen; Wenbing Song; Luke S Chang; Hong-Chiang Chang; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

4.  Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer.

Authors:  Simone Punt; Gert Jan Fleuren; Eva Kritikou; Erik Lubberts; J Baptist Trimbos; Ekaterina S Jordanova; Arko Gorter
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

5.  Mast cell chymase affects the proliferation and metastasis of lung carcinoma cells in vitro.

Authors:  Yuan Jiang; Yudan Wu; William James Hardie; Xiaoying Zhou
Journal:  Oncol Lett       Date:  2017-06-28       Impact factor: 2.967

6.  Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.

Authors:  Andreas Josefsson; Hani Adamo; Peter Hammarsten; Torvald Granfors; Pär Stattin; Lars Egevad; Anna Engström Laurent; Pernilla Wikström; Anders Bergh
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

7.  Differences of the immune cell landscape between normal and tumor tissue in human prostate.

Authors:  E Zhang; F Dai; Y Mao; W He; F Liu; W Ma; Y Qiao
Journal:  Clin Transl Oncol       Date:  2019-05-10       Impact factor: 3.405

8.  Prognostic value of tumor-infiltrating mast cells in outcome of patients with esophagus squamous cell carcinoma.

Authors:  Ashraf Fakhrjou; Seid Mahdi Niroumand-Oscoei; Mohamad Hosein Somi; Morteza Ghojazadeh; Shahnaz Naghashi; Shabnam Samankan
Journal:  J Gastrointest Cancer       Date:  2014-03

9.  Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.

Authors:  Dietmar M W Zaiss; Jorg van Loosdregt; Andrea Gorlani; Cornelis P J Bekker; Andrea Gröne; Maria Sibilia; Paul M P van Bergen en Henegouwen; Rob C Roovers; Paul J Coffer; Alice J A M Sijts
Journal:  Immunity       Date:  2013-01-17       Impact factor: 31.745

Review 10.  Emerging strategies for cancer immunoprevention.

Authors:  J C Roeser; S D Leach; F McAllister
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.